GB201609517D0 - Enzyme inhibitors - Google Patents

Enzyme inhibitors

Info

Publication number
GB201609517D0
GB201609517D0 GBGB1609517.6A GB201609517A GB201609517D0 GB 201609517 D0 GB201609517 D0 GB 201609517D0 GB 201609517 A GB201609517 A GB 201609517A GB 201609517 D0 GB201609517 D0 GB 201609517D0
Authority
GB
United Kingdom
Prior art keywords
enzyme inhibitors
inhibitors
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1609517.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalvista Pharmaceuticals Ltd
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Priority to GBGB1609517.6A priority Critical patent/GB201609517D0/en
Publication of GB201609517D0 publication Critical patent/GB201609517D0/en
Priority to KR1020227025232A priority patent/KR20220107319A/en
Priority to IL263235A priority patent/IL263235B/en
Priority to MDE20190408T priority patent/MD3464271T2/en
Priority to ES17728593T priority patent/ES2805027T3/en
Priority to PL17728593T priority patent/PL3464271T3/en
Priority to PT177285939T priority patent/PT3464271T/en
Priority to MA45127A priority patent/MA45127B1/en
Priority to SG11201809922YA priority patent/SG11201809922YA/en
Priority to MX2018014188A priority patent/MX2018014188A/en
Priority to UAA201811720A priority patent/UA123735C2/en
Priority to JP2018560068A priority patent/JP6884801B2/en
Priority to CN201780034028.9A priority patent/CN109311847B/en
Priority to EP20173514.9A priority patent/EP3760622A1/en
Priority to SG10201913616UA priority patent/SG10201913616UA/en
Priority to CN202110792609.7A priority patent/CN113387933A/en
Priority to PCT/GB2017/051546 priority patent/WO2017207983A1/en
Priority to CA3025718A priority patent/CA3025718A1/en
Priority to RU2020140891A priority patent/RU2020140891A/en
Priority to IL293304A priority patent/IL293304A/en
Priority to KR1020187038212A priority patent/KR102424709B1/en
Priority to EP17728593.9A priority patent/EP3464271B1/en
Priority to MEP-2020-150A priority patent/ME03794B/en
Priority to DK17728593.9T priority patent/DK3464271T3/en
Priority to BR112018074395-0A priority patent/BR112018074395A2/en
Priority to HUE17728593A priority patent/HUE049918T2/en
Priority to RU2018141881A priority patent/RU2739447C2/en
Priority to RS20200866A priority patent/RS60600B1/en
Priority to AU2017275820A priority patent/AU2017275820B2/en
Priority to LTEP17728593.9T priority patent/LT3464271T/en
Priority to SI201730324T priority patent/SI3464271T1/en
Priority to US16/301,192 priority patent/US11180484B2/en
Priority to PH12018502355A priority patent/PH12018502355A1/en
Priority to CL2018003213A priority patent/CL2018003213A1/en
Priority to MX2021008342A priority patent/MX2021008342A/en
Priority to CONC2018/0012894A priority patent/CO2018012894A2/en
Priority to ZA2018/08639A priority patent/ZA201808639B/en
Priority to ECSENADI201894983A priority patent/ECSP18094983A/en
Priority to HRP20201131TT priority patent/HRP20201131T1/en
Priority to CY20201100735T priority patent/CY1123223T1/en
Priority to AU2021200140A priority patent/AU2021200140B2/en
Priority to JP2021080175A priority patent/JP7109012B2/en
Priority to US17/480,424 priority patent/US20220002275A1/en
Ceased legal-status Critical Current

Links

GBGB1609517.6A 2016-05-31 2016-05-31 Enzyme inhibitors Ceased GB201609517D0 (en)

Priority Applications (43)

Application Number Priority Date Filing Date Title
GBGB1609517.6A GB201609517D0 (en) 2016-05-31 2016-05-31 Enzyme inhibitors
EP17728593.9A EP3464271B1 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
KR1020187038212A KR102424709B1 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
MEP-2020-150A ME03794B (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
MDE20190408T MD3464271T2 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
IL263235A IL263235B (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
PL17728593T PL3464271T3 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
PT177285939T PT3464271T (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
MA45127A MA45127B1 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as inhibitors of plasma kallikrein
SG11201809922YA SG11201809922YA (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
MX2018014188A MX2018014188A (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors.
UAA201811720A UA123735C2 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
JP2018560068A JP6884801B2 (en) 2016-05-31 2017-05-31 Pyrazole derivative as plasma kallikrein inhibitor
CN201780034028.9A CN109311847B (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
EP20173514.9A EP3760622A1 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
SG10201913616UA SG10201913616UA (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
CN202110792609.7A CN113387933A (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
DK17728593.9T DK3464271T3 (en) 2016-05-31 2017-05-31 PYRAZOLD DERIVATIVES AS PLASMA CALLICREIN INHIBITORS
CA3025718A CA3025718A1 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
RU2020140891A RU2020140891A (en) 2016-05-31 2017-05-31 PYRAZOL DERIVATIVES AS CALLICREIN INHIBITORS
IL293304A IL293304A (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
KR1020227025232A KR20220107319A (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
US16/301,192 US11180484B2 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
ES17728593T ES2805027T3 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as inhibitors of plasma kallikrein
PCT/GB2017/051546 WO2017207983A1 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
BR112018074395-0A BR112018074395A2 (en) 2016-05-31 2017-05-31 pyrazole derivatives as inhibitors of plasma kallikrein
HUE17728593A HUE049918T2 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
RU2018141881A RU2739447C2 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as kallikrein inhibitors
RS20200866A RS60600B1 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
AU2017275820A AU2017275820B2 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
LTEP17728593.9T LT3464271T (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
SI201730324T SI3464271T1 (en) 2016-05-31 2017-05-31 Pyrazole derivatives as plasma kallikrein inhibitors
PH12018502355A PH12018502355A1 (en) 2016-05-31 2018-11-08 Enzyme inhibitors
CL2018003213A CL2018003213A1 (en) 2016-05-31 2018-11-12 Enzymatic inhibitors
MX2021008342A MX2021008342A (en) 2016-05-31 2018-11-16 Pyrazole derivatives as plasma kallikrein inhibitors.
CONC2018/0012894A CO2018012894A2 (en) 2016-05-31 2018-11-28 Pyrazole derivatives as plasma kallikrein inhibitors
ZA2018/08639A ZA201808639B (en) 2016-05-31 2018-12-20 Pyrazole derivatives as plasma kallikrein inhibitors
ECSENADI201894983A ECSP18094983A (en) 2016-05-31 2018-12-28 PIRAZOLE DERIVATIVES AS INHIBITORS OF PLASMA CALICREIN
HRP20201131TT HRP20201131T1 (en) 2016-05-31 2020-07-17 Pyrazole derivatives as plasma kallikrein inhibitors
CY20201100735T CY1123223T1 (en) 2016-05-31 2020-08-06 PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
AU2021200140A AU2021200140B2 (en) 2016-05-31 2021-01-12 Pyrazole derivatives as plasma kallikrein inhibitors
JP2021080175A JP7109012B2 (en) 2016-05-31 2021-05-11 Pyrazole derivatives as plasma kallikrein inhibitors
US17/480,424 US20220002275A1 (en) 2016-05-31 2021-09-21 Enzyme inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1609517.6A GB201609517D0 (en) 2016-05-31 2016-05-31 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
GB201609517D0 true GB201609517D0 (en) 2016-07-13

Family

ID=56410776

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1609517.6A Ceased GB201609517D0 (en) 2016-05-31 2016-05-31 Enzyme inhibitors

Country Status (2)

Country Link
GB (1) GB201609517D0 (en)
MA (1) MA45127B1 (en)

Also Published As

Publication number Publication date
MA45127B1 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
IL287113A (en) Smyd inhibitors
GB201421083D0 (en) Enzyme inhibitors
GB201421088D0 (en) New enzyme inhibitors
EP3160477A4 (en) Prmt5 inhibitors and uses thereof
EP3160466A4 (en) Prmt5 inhibitors and uses thereof
EP3177288A4 (en) Prmt5 inhibitors and uses thereof
IL269196A (en) Novel inhibitors
EP3116503A4 (en) Hptp-beta inhibitors
IL248895A0 (en) Phosphatidylinositol -kinase inhibitors
GB201416446D0 (en) New enzyme inhibitor compounds
GB201421085D0 (en) New enzyme inhibitors
EP3303324A4 (en) Novel corrosion inhibitors
IL265139B (en) Dopamine-b-hydroxylase inhibitors
ZA201907136B (en) Ip6k inhibitors
GB201612860D0 (en) Inhibitors
GB201501004D0 (en) Inhibitors
HK1251572A1 (en) Triaza-spirodecanones as ddr1 inhibitors
EP3148971A4 (en) Deubiquitinase inhibitors
HK1244790A1 (en) Bace1 inhibitors
IL274550A (en) Dopamine-b-hydroxylase inhibitors
EP3525786A4 (en) Kdm5 inhibitors
IL247025A0 (en) Enzyme inhibitors
PL3322724T3 (en) Il-26 inhibitors
GB201520949D0 (en) Inhibitors
EP3180003A4 (en) Pkc-epsilon inhibitors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)